CAS No.15663-27-1,Cisplatin Suppliers

Products Categories

Pharmaceutical (252)
Others (75)
Organic Chemicals (46)
Catalyst and Auxiliary (14)
Reagent (11)
Plant Extract (8)
Materials (5)
Synthetic Flavours & Fragrances (2)
Basic Inorganic Chemicals (1)

Basic Information

Molecular Structure:
CAS No.:	15663-27-1
Name:	Cisplatin
Article Data:	205

Formula:	Cl₂H₆N₂Pt
Molecular Weight:	300.047
Synonyms:	Neoplatin;Platosin;cis-dichlorodi-ammine platinum(ii);cis-Diammineplatinum(II) dichloride;cis-Dichlorodiamminoplatinum(II);CPDD;cisPt(II);cis-Platinum(II) diaminodichloride;Platinum(II), diamminedichloro-, cis-;Biocisplatinum;Cisplatyl;DDP (antitumor agent);Cisplatinum;azane; platinum(+2) cation; dichloride;
EINECS:	239-733-8
Density:	3.7 g/cm³
Melting Point:	340 °C (dec.)(lit.)
Solubility:	<0.1 g/100 mL at 19 °C in water
Appearance:	Orange-yellow to deep yellow solid or powder
Hazard Symbols:	T
Risk Codes:	45-25-41-60-46-42/43-36/37/38
Safety:	53-26-39-45-99-36/37/39-22
Transport Information:	UN 3288 6.1/PG 2
PSA:	24.72000
LogP:	2.02430

Synthetic route

: ammonium acetate

: 10025-99-7
potassium tetrachloroplatinate(II)

: potassium chloride

: 15663-27-1
cisplatin

Conditions

Conditions	Yield
In water at 100℃; for 0.233333h; Temperature; Time; Concentration; Microwave irradiation;	90%

...Expand

: 7647-01-0
hydrogenchloride

: pyrophosphatotetraamminediplatinum(II)

: 15663-27-1
cisplatin

Conditions

Conditions	Yield
In hydrogenchloride Pt complex transformed in HCl soln. at 25°C with no oxidants;	85%

: cis-diaminediiodoplatinum(II)

: potassium chloride

: 15663-27-1
cisplatin

Conditions

Conditions	Yield
Stage #1: cis-diaminediiodoplatinum(II) With silver nitrate In water at 80℃; for 2h; Stage #2: potassium chloride at 80℃; for 0.166667h;	73%
Stage #1: cis-diaminediiodoplatinum(II) With silver nitrate In water at 80℃; for 0.333333h; Darkness; Stage #2: potassium chloride at 0℃; for 0.25h;	60%
Stage #1: cis-diaminediiodoplatinum(II) With silver nitrate In water at 50℃; for 24h; Stage #2: potassium chloride
Stage #1: cis-diaminediiodoplatinum(II) With silver nitrate In water at 70℃; for 1.5h; Darkness; Stage #2: potassium chloride In water at 70℃; for 1h; Darkness;

: ammonium platinum(II) chloride

: 7664-41-7
ammonia

: 15663-27-1
cisplatin

Conditions

Conditions	Yield
In water byproducts: {Pt(NH3)4}{PtCl4}; mixing of a soln. of (NH4)2(PtCl4) in cold H2O with 5 n NH3 soln. and storing for 12-18 h at 0°C;; washing with ice water and treatment on a filter with boiling H2O; addn. of half concd. HCl soln. to the soln. and filtration after 24 h; washing with ice water, then with alcohol; drying in air;;	66.7%
In water byproducts: {Pt(NH3)4}{PtCl4}; mixing of a soln. of (NH4)2(PtCl4) in cold H2O with 5 n NH3 soln. and storing for 12-18 h at 0°C;; washing with ice water and treatment on a filter with boiling H2O; addn. of half concd. HCl soln. to the soln. and filtration after 24 h; washing with ice water, then with alcohol; drying in air;;	66.7%
With NH4-oxalate In water formation from (NH4)2(PtCl4), aq. NH4 oxalate and NH3 soln.;;
With NH4-oxalate In water formation from (NH4)2(PtCl4), aq. NH4 oxalate and NH3 soln.;;

: cis-diaminediiodoplatinum(II)

: 7647-14-5
sodium chloride

: 15663-27-1
cisplatin

Conditions

Conditions	Yield
With silver nitrate In N,N-dimethyl acetamide; water at 60℃; Darkness;	61.7%

: ammonium acetate

: 7647-01-0
hydrogenchloride

: magnus green salt

: 15663-27-1
cisplatin

: 26035-31-4, 14913-33-8, 15663-27-1
transplatin

Conditions

Conditions	Yield
With acetic acid In water Magnus salt suspended in water; ammmonium acetate added; pH adjusted to 5.4 (acetic acid); mixt. heated for 1 h; cooled; filtered; concd. HCl added; cis-Pt(NH3)2Cl2 sepd.; soln. heated at about 95°C for 1.5 h; cooled; trans-Pt(NH3)2Cl2 sepd.; elem. anal.;	A 40% B 39%

...Expand

: cis-{Pt(glycyl-α-alanine)2(NH3)2}*H2O

: 15663-27-1
cisplatin

Conditions

Conditions	Yield
With HCl In not given Joergensen splitting in the presence of concd. HCl;	10%

: cis-diamminediaquaplatinum(II)

: potassium chloride

: 15663-27-1
cisplatin

: ammonium carbonate

: hydrogen chloroplatinate(II)

: 15663-27-1
cisplatin

Conditions

Conditions	Yield
In not given pptn. from H2(PtCl4) soln. with (NH4)2CO3;;
In not given pptn. from H2(PtCl4) soln. with (NH4)2CO3;;

: hydrogen chloroplatinate(II)

: 7664-41-7
ammonia

: 15663-27-1
cisplatin

Conditions

Conditions	Yield
In ammonia byproducts: {Pt(NH3)4}Cl2*H2O; formation by treating of H2(PtCl4) soln. with excess NH3;;
In ammonia byproducts: {Pt(NH3)4}{PtCl4}; formation by treating a cold H2(PtCl4) soln. with NH3 soln.;; recrystn. of the ppt. in boiling H2O;;
In not given addn. of NH3 to H2(PtCl4);;
In ammonia byproducts: {Pt(NH3)4}Cl2*H2O; aq. ammonia=NH3; formation by treating of H2(PtCl4) soln. with excess NH3;;
In ammonia byproducts: {Pt(NH3)4}{PtCl4}; aq. ammonia=NH3; formation by treating a cold H2(PtCl4) soln. with NH3 soln.;; recrystn. of the ppt. in boiling H2O;;

Downstream Products

Total:265 Page 1 of 7 1 2 3 4 5 6 …7 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 15663-27-1

History

The compound cis-PtC_l2(NH₃)₂was first described by M. Peyrone in 1845. Approved for clinical use by the United States Food and Drug Administration (FDA) in 1978.

Specification

The Cisplatin, with the CAS registry number 15663-27-1,is also known as cis-Diaminedichloroplatinum(II). It belongs to the product categories of ammine metal halide;Anti Cancer Reagents;chemical reaction,pharm,electronic,materials. Its EINECS number is 239-733-8. This chemical's molecular formula is Cl2H6N2Pt and molecular weight is 300.05. What's more,Its systematic name is Cisplatin.It is a Crystalline which is an inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.

You can still convert the following datas into molecular structure:
(1)SMILES:[NH3][Pt]([NH3])(Cl)Cl;
(2)Std. InChI:InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2;
(3)Std. InChIKey:LXZZYRPGZAFOLE-UHFFFAOYSA-L;

Safety Information of Cisplatin:
The Cisplatin is Irritating to eyes, respiratory system and skin and it may cause sensitization by inhalation and skin contact. so it should avoid exposure - obtain special instructions before use. It is risk of serious damage to the eyes. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. When you use it ,wear suitable protective clothing, gloves and eye/face protection. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)

The toxicity data of Cisplatin are as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	TDLo	unreported	19200ug/kg/12 (19.2mg/kg)	SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR	Journal of Pediatrics. Vol. 103, Pg. 1006, 1983.
dog	LDLo	intravenous	2500ug/kg (2.5mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" BLOOD: METHEMOGLOBINEMIA-CARBOXYHEMOGLOBIN GASTROINTESTINAL: OTHER CHANGES	Toxicology and Applied Pharmacology. Vol. 25, Pg. 230, 1973.
frog	LD50	parenteral	17mg/kg (17mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Journal of Comparative Pathology. Vol. 103, Pg. 387, 1990.
guinea pig	LD50	intraperitoneal	9700ug/kg (9.7mg/kg)	SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR	Toxicology and Applied Pharmacology. Vol. 33, Pg. 320, 1975.
human	TDLo	intradermal	40ng/kg (.00004mg/kg)	SKIN AND APPENDAGES (SKIN): PRIMARY IRRITATION: AFTER TOPICAL EXPOSURE SKIN AND APPENDAGES (SKIN): CORROSIVE: AFTER TOPICAL EXPOSURE	Cancer Research. Vol. 35, Pg. 2766, 1975.
human	TDLo	intravenous	500ug/kg/13D- (.5mg/kg)	BLOOD: OTHER CHANGES KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: RENAL FUNCTION TESTS DEPRESSED	Cancer Treatment Reports. Vol. 62, Pg. 693, 1978.
human	TDLo	intravenous	1500ug/kg/6D- (1.5mg/kg)	BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE KIDNEY, URETER, AND BLADDER: RENAL FUNCTION TESTS DEPRESSED SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR	Cancer Chemotherapy Reports, Part 1. Vol. 57, Pg. 191, 1973.
human	TDLo	intravenous	2500ug/kg (2.5mg/kg)	KIDNEY, URETER, AND BLADDER: RENAL FUNCTION TESTS DEPRESSED BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" GASTROINTESTINAL: NAUSEA OR VOMITING	Cancer Chemotherapy Reports, Part 1. Vol. 59, Pg. 647, 1975.
human	TDLo	intravenous	72mg/kg/25D-I (72mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING	Cancer Treatment Reports. Vol. 62, Pg. 1591, 1978.
mammal (species unspecified)	LDLo	intravenous	8mg/kg (8mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 28(4), Pg. 285, 2000.
man	TDLo	intravenous	2140ug/kg/5D- (2.14mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Japanese Journal of Medicine. Vol. 23, Pg. 283, 1984.
man	TDLo	parenteral	2140ug/kg/5D- (2.14mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Nippon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine. Vol. 72, Pg. 1426, 1983.
monkey	LDLo	intravenous	250ug/kg (.25mg/kg)		Cancer Vol. 33, Pg. 1219, 1974.
mouse	LD50	intramuscular	17900ug/kg (17.9mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BLOOD: NORMOCYTIC ANEMIA	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 723, 1982.
mouse	LD50	intraperitoneal	6600ug/kg (6.6mg/kg)		Journal of Medicinal Chemistry. Vol. 34, Pg. 414, 1991.
mouse	LD50	intravenous	11mg/kg (11mg/kg)		Archives of Toxicology, Supplement. Vol. 7, Pg. 90, 1984.
mouse	LD50	oral	32700ug/kg (32.7mg/kg)	LUNGS, THORAX, OR RESPIRATION: CYANOSIS GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED	Kiso to Rinsho. Clinical Report. Vol. 15, Pg. 5669, 1981.
mouse	LD50	parenteral	22mg/kg (22mg/kg)		International Journal of Radiation Oncology, Biology, Physics. Vol. 5, Pg. 1417, 1979.
mouse	LD50	subcutaneous	13mg/kg (13mg/kg)		Journal de Pharmacie de Belgique. Vol. 41, Pg. 286, 1986.
mouse	LD50	unreported	10900ug/kg (10.9mg/kg)		Gan to Kagaku Ryoho. Cancer and Chemotherapy. Vol. 13, Pg. 280, 1986.
rat	LD	unreported	> 5mg/kg (5mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Journal of Toxicological Sciences. Vol. 24, Pg. 337, 1999.
rat	LD50	intramuscular	9200ug/kg (9.2mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BLOOD: NORMOCYTIC ANEMIA GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 723, 1982.
rat	LD50	intraperitoneal	6400ug/kg (6.4mg/kg)		Journal of Toxicological Sciences. Vol. 18, Pg. 31, 1993.
rat	LD50	intravenous	8mg/kg (8mg/kg)	KIDNEY, URETER, AND BLADDER: OTHER CHANGES	JNCI, Journal of the National Cancer Institute. Vol. 67, Pg. 201, 1981.
rat	LD50	oral	25800ug/kg (25.8mg/kg)	BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: NORMOCYTIC ANEMIA	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 723, 1982.
rat	LD50	subcutaneous	8100ug/kg (8.1mg/kg)	LUNGS, THORAX, OR RESPIRATION: CYANOSIS GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" KIDNEY, URETER, AND BLADDER: URINE VOLUME INCREASED	Kiso to Rinsho. Clinical Report. Vol. 15, Pg. 5669, 1981.